DE
PACB icon

DV Equities’s Pacific Biosciences PACB Stock Holding History

DV Equities’s Portfolio PACB Stock Details PACB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		$187 Buy
+100
New +$192 ﹤0.01% 737

Other funds holding PACB

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SoftBank Group
SoftBank Group Tokyo, Japan $18.2B AUM 177.65% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

DV Equities's PACB Position: Q4 2025 in Review

DV Equities opened a new position in Pacific Biosciences (PACB) in Q4 2025: 100 shares worth $187. The stake represents ﹤0.01% of the portfolio and ranks #737 among its holdings.

215 funds tracked by Wall St. Rank hold PACB as of Q4 2025.

  • DV Equities held 100 shares of Pacific Biosciences worth $187 as of Q4 2025.
  • Pacific Biosciences was a new DV Equities position in Q4 2025.
  • Pacific Biosciences made up ﹤0.01% of DV Equities's portfolio in Q4 2025, its #737 holding.
  • 215 funds tracked by Wall St. Rank held Pacific Biosciences as of Q4 2025.

Based on DV Equities's 13F filing for Q4 2025, filed 17 Feb 2026.